These lab-built options weren't formulated with recreational use in mind. From the 1990s, John W. Huffman plus a workforce of fellow chemists at Clemson University developed a number of the initially formulation for synthetic cannabinoid receptor agonists (SCRAs), a household of substances that imitate the physiological and psychological impacts of